Ascendis Pharma A/S' (NASDAQ:ASND) Popularity With Investors Is Under Threat From Overpricing
Evercore Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $220
Ascendis Pharma's YORVIPATH Now Commercially Available In The U.S. For The Treatment Of Hypoparathyroidism In Adults
Jefferies Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $194
A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $167 to $211
Express News | Ascendis Pharma A/S : Jefferies Raises Target Price to $194 From $191
factors that put the rise on are not from a rebound but from news, either way the price is above the price before financial reporting
